💭Can you imagine that you had a tool that could predict the risk of developing brain mets in pts with HER2+ MBC?
😮Stop dreaming, this is real
🎯New generation biomarkers
🌍 International colab, 215 pts
Come by and discuss our poster at #SABCS25 on Dec 12th
@OncoAlert
📣 Calling future oncologists who have completed at least 1y of #oncology training! Apply by 7/9/25 to attend @FDAOncology-@ASCO Fellows’ Day Workshop: https://t.co/TyEcnxFtqL
👉 9/25/25: in person (ASCO headquarters, DC area)
or
👉 1/29/26: virtual
See you there! #MedTwitter
The #ASCO25#OncoAlertTOP10 Abstracts in #GUOncology These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸
#ProstateCancer#BladderCancer#kidneyCancer
⭐Abs 4518 SURE-02: NEOADJUVANT SACITUZUMAB GOVITECAN PLUS PEMBROLIZUMAB, FOLLOWED BY RESPONSE-ADAPTED BLADDER SPARING AND ADJUVANT PEMBRO, IN MUSCLE-INVASIVE BLADDER CANCER
⭐Abs 4521 AREN1721: AXITINIB+NIVOLUMAB COMBINATION THERAPY VS. SINGLE AGENT NIVOLUMAB FOR THE TREATMENT OF TFE/TRANSLOCATION RENAL CELL CARCINOMA ACROSS ALL AGE GROUPS
⭐Abs 5000 CAN-2409+PRODRUG IN COMBINATION WITH STANDARD OF CARE EXTERNAL BEAM RADIATION (EBRT) FOR NEWLY DIAGNOSED LOCALIZED PROSTATE CANCER
⭐Abs LBA5006 SUNRISE-4: TAR-200 + CETRELIMAB OR CET ALONE AS NEOADJUVANT THERAPY IN MUSCLE-INVASIVE BLADDER CANCER INELIGIBLE FOR OR REFUSE NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY
⭐Abs 5019 TALAPRO-2: HOMOLOGOUS RECOMBINATION REPAIR ALTERATIONS BY GENE SUBGROUP AND POTENTIAL ASSOCIATIONS WITH EFFICACY IN THE HRR-DEFICIENT POPULATION
⭐Abs 4500 CHECKMATE 901 PHASE 3 TRIAL: IPI/NIVO VS GEM/CARBO AS 1L THERAPY IN CISPLATIN-INELIGIBLE
PATIENTS WITH MUC
⭐Abs 4514 FIVE-YEAR FOLLOW-UP KEYNOTE-564 STUDY OF ADJUVANT PEMBROLIZUMAB (PEMBRO)
FOR THE TREATMENT OF CLEAR CELL RENAL CELL CARCINOMA
⭐Abs 4516 PDIGREE (ALLIANCE A031704): IPILIMUMAB AND NIVOLUMAB IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA (MCCRCC)
⭐Abs 4517
CREST: SASANLIMAB IN COMBINATION WITH BACILLUS CALMETTE-GUÉRIN (BCG) IN BCG-NAIVE, HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): EVENT-FREE SURVIVAL (EFS)
⭐Abs 4506 COMBINATION CASDATIFAN PLUS CABOZANTINIB EXPANSION COHORT OF PHASE 1 ARC-20
STUDY IN PREVIOUSLY TREATED PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA
⭐Abs LBA4513 ENLIGHTED INTERIM RESULTS OF EFFICACY AND SAFETY OF PADELIPORFIN VASCULAR TARGETED PHOTODYNAMIC THERAPY IN TREATMENT OF LOW-GRADE UPPER TRACT UROTHELIAL CANCER
⭐Abs 4520 CLONEVO: PREOPERATIVE ABEMACICLIB FOR CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER (MIBC) WITH MOLECULAR RESPONSE ASSESSMENT
⭐Abs LBA5012 AN OPEN LABEL RANDOMIZED NON-INFERIORITY TRIAL COMPARING ADJUVANT PLATINUM PLUS PACLITAXEL TO PLATINUM PLUS 5-FU AFTER CURATIVE RESECTION IN HIGH-RISK PENILE CARCINOMA
Lead @nataliagandur@ReginaBarCar@yekeduz_emre@weoncologists
Faculty: @apolo_andrea@DrChoueiri@PGrivasMDPhD@ravikanesvaran@neerajaiims@amerseburger@drenriquegrande@Silke_Gillessen
Ping GU Faculty
@montypal@crisbergerot@DrDanielHeng@DrChoueiri@TiansterZhang@HHammersMD@sonpavde@drenriquegrande@scserendipity1@EfstathiouEleni@tompowles1@BraunMDPhD@nataliagandur@cdanicas@DrYukselUrun
#OncoAlertAF
@acampsmalea@BRicciutiMD@HHorinouchi@FadiHaddad_MD@Abdallah81MD@FernandoOnco@ElisaAgostinett@to_be_elizabeth@bavilima@realbowtiedoc@Erman_Akkus@Lucarecco@GaiaGriguolo@JankovicK
Check out this just published @JGeriOnc paper on the patterns of presentation, treatment, and survival among older adults with #MetastaticBreastCancer. Use the link below to access the full paper until July 08 ⬇️
https://t.co/QpxcnMhklP
✍️@skeffimo@stolaney1@nlinmd@DrRFreedman
#OlderAdultsWithBreastCancer #GeriOnc #BreastCancer #geriatricOncology #MBC
Wonderful talk by Nadia Harbeck on treatment approaches for early stage HER2+ BC--> nice work on tailoring therapy to the individual patient
@SG_BCC#bcsm@Prof_Nadia_H
No one better than Martine Piccart to review the lessons learned over 20 years of adjuvant trastuzumab use.
Many wins, some failures.
One major thing missing: a validated biomarker besides HER2 positivity.
Could #HER2DX fill this gap? Validation ongoing
#SGBCC2025
This is Uruguay:
- 0% tax on foreign income for 11 years
- Permanent residency in just 2 years
- Less corrupt than the US
It is the safest country in South America.
Here are 11 reasons why the “Switzerland of South America” is a hidden gem:
El ejercicio de fuerza y desarrollar la musculatura es importante para la salud metabólica. El músculo esquelético regula más del 75% de la eliminación de glucosa mediada por insulina, lo que ayuda a controlar la glucosa y los lípidos al tiempo que reduce el riesgo de diabetes.
Estoy profundamente conmovido por las imágenes provenientes desde Venezuela. El gran pueblo venezolano se ha levantado con justa indignación ante un inepto intento de robar una elección. Inspirados por la valentía de María Corina Machado, los venezolanos han perdido el miedo. Las FF.AA no van a reprimir a sus hermanos. Así terminan las tiranías. ¡Viva Venezuela Libre! 🇻🇪
🤔 How have CDK4/6i impacted the OS in first-line for HR+/HER2- advanced breast cancer?
📣 Delighted to share this editorial in @Annals_Oncology, coauthored with @MOliveira_MD
https://t.co/elfvrvVKTi